[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652033":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":50,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Sichuan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[211At]MABG","EXPERIMENTAL","Fractionated Dose",[13],"Drug: [211At]MABG",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Rong TIAN, MD","West China Hospital","PRINCIPAL_INVESTIGATOR",[25,29],{"name":21,"role":26,"phone":27,"phoneExt":18,"email":28},"CONTACT","+86 189 8060 1586","rongtiannuclear@126.com",{"name":30,"role":26,"phone":31,"phoneExt":18,"email":32},"Xiaoao WU, PHD","+86 189 8060 2715","allenfire511@163.com",[34],{"facility":22,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Chengdu","Sichuan","000000","China","CN",{"type":42,"coordinates":43},"Point",[44,45],104.06667,30.66667,{"lat":45,"lon":44},[48],{"name":49,"role":26,"phone":27,"phoneExt":18,"email":28},"Rong TIAN",{"type":23,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Rong Tian","Professor","100652033","early-phase-1-safety-tolerability-and-preliminary-efficacy-of-211atmabg-in-patients-with-relapsed-or-refractory-neuroblastoma-100652033",false,"NCT07767630","Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma","An Exploratory Proof-of-Concept (POC) Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Fractionated Dosing of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma (Including a Run-in Phase)","Inclusion Criteria:\n\n1. Patients diagnosed with MIBG avid lesions, high-risk neuroblastoma per the Revised International Neuroblastoma Response Criteria (Revised INRC), with refractory, relapsed, or progressive disease.\n2. All measurable soft tissue lesions must be MIBG-avid.\n3. Age ≥ 1 year at enrollment.\n4. Lansky performance status ≥ 50%.\n5. Adequate organ function and hematologic parameters.\n\nExclusion Criteria:\n\n1. Antibody-based immunotherapy within fewer than 5 half-lives or 30 days (whichever is shorter), or who have not yet recovered from adverse effects of any biologic therapy.\n2. Treatment with \\[¹³¹I\\]MIBG or Lu177 targeted radionuclide therapy less than 3 months of last administration.\n3. Autologous stem cell transplant \\\u003C12 weeks, or Allogeneic stem cell transplant \\\u003C4 months (patients \\>4 months post-transplant must be free of active GVHD).\n4. Radiotherapy within 2 weeks prior to the first study dose (However, patients with a single-site irradiation that remains MIBG avid may be enrolled.) or extensive-field radiotherapy (e.g., craniospinal, whole abdomen, whole lung, or \\>50% of bone marrow area) within 12 weeks prior to the first study dose.\n5. Renal Insufficiency.\n6. Active Infections.","ALL","1 Year","100 Years",{"count":64,"type":65},10,"ESTIMATED","INTERVENTIONAL",[68],"EARLY_PHASE1","Fractionated dosing of \\[211At\\]MABG Radiotherapy in Relapsed\u002FRefractory Neuroblastoma",[71],"Neuroblastoma (NB)",[73],"Radiopharmaceutical","2026-08-19",{"date":76,"type":77},"2026-08-21","ACTUAL",{"date":79,"type":77},"2026-07-21",{"date":81,"type":65},"2027-06-30",{"name":5,"class":6},1]